Mass Tort brief
Mass Tort Update: Courts Reshape Liability Rules
Key rulings and settlements reshape product-liability risks across major pharmaceutical and medical device cases.
Mass Tort
Chemours and DuPont settled with North Carolina families to avoid a public trial — protecting their corporate balance sheets from a landmark liability precedent.
BackgroundPFAS (per- and polyfluoroalkyl substances) are highly persistent industrial chemicals that do not break down in the human body or the environment. Before this private settlement, local residents sued the chemical firms for discharging the compounds into their local water supplies.
- The out-of-court settlement cancels a landmark federal bellwether trial in Raleigh that was expected to set the pricing for thousands of similar claims.
- The manufacturers kept the financial terms confidential, preventing public disclosure of their overall liability exposure and protecting their corporate share prices from sudden market shocks.
- North Carolina's Attorney General publicly criticized a separate $450M federal EPA deal with Chemours, potentially encouraging local communities to file further independent actions.
Mass Tort
By narrowing judges' power to screen out expert science, the court handed 500 plaintiffs their leverage back — Kenvue now faces juries, and pressure toward a settlement in the billions.
BackgroundMultidistrict litigation consolidates similar personal injury claims before a single judge to speed up pre-trial discovery and coordinate expert testimony. Under federal rules, judges act as gatekeepers to ensure scientific witnesses use reliable and generally accepted methodologies.
- The Second Circuit ruled that the trial judge exceeded her authority by conducting an overly restrictive review of the plaintiffs' medical experts.
- Judges also rejected the manufacturer's preemption defense, confirming that federal drug laws do not block companies from adding stronger pregnancy warnings to their packaging.
- The decision remands over 500 lawsuits to the trial court, immediately restoring major financial risks for consumer health spin-off Kenvue.
Mass Tort
Pfizer's preemptive settlement shuts down the birth-control litigation before it can scale — eliminating the risk of multi-billion-dollar jury awards.
BackgroundDepo-Provera is an injectable contraceptive that has been widely prescribed to millions of women globally since the 1990s. More than 5,800 federal lawsuits allege that long-term use of the shot is linked to the development of meningiomas.
- The settlement in principle was reached unusually early in the litigation, halting the court's scheduled Daubert hearings on scientific evidence.
- A rescheduled case management conference in late July will let both parties present the finalized settlement framework to the presiding judge.
- By settling before public trials begin, Pfizer protects its broader product portfolio from the reputational fallout that frequently accompanies public medical testimony.
Mass Tort
The start of federal trials puts baby formula marketing on trial — testing whether manufacturers must compensate families for hospital-promoted infant food.
BackgroundNecrotizing Enterocolitis is a severe, often fatal disease where tissue in the large intestine becomes inflamed and dies. Plaintiffs allege that manufacturers Abbott and Mead Johnson heavily marketed cow's milk formulas without warning that they increase risks in premature infants.
- More than 810 cases are currently centralized before Chief Judge Rebecca Pallmeyer, making it one of the most significant active medical dockets.
- An Illinois state appeals court recently overturned a separate $60M jury verdict against Mead Johnson, showing how volatile the state-court litigation remains.
- A second federal bellwether trial focusing on Abbott Laboratories' Similac formula is scheduled for August 10, creating back-to-back courtroom challenges for the industry.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.